<code id='1F68ACF2C8'></code><style id='1F68ACF2C8'></style>
    • <acronym id='1F68ACF2C8'></acronym>
      <center id='1F68ACF2C8'><center id='1F68ACF2C8'><tfoot id='1F68ACF2C8'></tfoot></center><abbr id='1F68ACF2C8'><dir id='1F68ACF2C8'><tfoot id='1F68ACF2C8'></tfoot><noframes id='1F68ACF2C8'>

    • <optgroup id='1F68ACF2C8'><strike id='1F68ACF2C8'><sup id='1F68ACF2C8'></sup></strike><code id='1F68ACF2C8'></code></optgroup>
        1. <b id='1F68ACF2C8'><label id='1F68ACF2C8'><select id='1F68ACF2C8'><dt id='1F68ACF2C8'><span id='1F68ACF2C8'></span></dt></select></label></b><u id='1F68ACF2C8'></u>
          <i id='1F68ACF2C8'><strike id='1F68ACF2C8'><tt id='1F68ACF2C8'><pre id='1F68ACF2C8'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:leisure time    Page View:895

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In